GHRP-2 Dosage, Reconstitution & Mixing Trends

Explore ghrp-2 calculator-entry dose, vial-size, BAC-water and self-reported frequency distributions. Research context is separate from live observations.

Anonymized ghrp-2 calculator entries are summarized by each chart's selected period. Frequency responses come from the separate vial-duration feature. Inputs are not verified administrations or unique people.

What GHRP-2 Is

GHRP-2 (pralmorelin) is a synthetic hexapeptide growth-hormone secretagogue, most often sourced for GH-axis and appetite research. It is approved in Japan as a single-dose diagnostic agent but has no FDA approval in the United States. It ships as a lyophilized powder you reconstitute with bacteriostatic water before use.[1]

GHRP-2 is a selective agonist of the ghrelin / growth-hormone-secretagogue receptor (GHS-R1a) expressed on pituitary somatotropes and hypothalamic neurons. Receptor activation stimulates GH release through a pathway independent of (but synergistic with) GHRH-receptor signaling, and also stimulates appetite via parallel ghrelin-mediated central pathways.[2] Unlike ipamorelin, GHRP-2 also weakly stimulates prolactin and ACTH/cortisol secretion.

A single-dose GHRP-2 stimulation test was validated in Japanese pediatric and adult cohorts (Chihara et al.) as a diagnostic alternative to the insulin-tolerance test for severe GH deficiency, supporting its 2006 Japanese regulatory approval.[3] Chronic dosing trials in cachexia (CP-424391-related work) and adult GH deficiency have been published but have not advanced to Phase 3.

Approved in Japan (GHRP Kaken) as a single-dose diagnostic for severe GH deficiency. Not FDA-approved in the United States. Research-grade material elsewhere.

GHRP-2 Research Sources

GHRP-2 Dosing Context

GHRP-2 has a reported half-life of ~30 min. The pharmacokinetic reference models an interval of once daily (often before bed); this is not a measured community cadence or a dosing recommendation. Very short-acting — it triggers a GH pulse and then clears within the hour, with no buildup. Many users dose two or three times a day to repeat the pulse. Pharmacokinetic source: Bowers et al. clinical GHRP-2 pharmacology studies. It is catalogued under Muscle Peptides on WPA.

GHRP-2 Community Calculator Data

91 GHRP-2 reconstitution calculations have been logged by the WPA community.

This is the lifetime header population. Each chart and its associated analysis below use their own selected period and denominator; frequency responses are a separate cohort.

These figures come from anonymized WPA peptide calculator sessions, not verified administrations or unique people. Separate modal inputs do not establish a joint protocol. They are community input statistics — not dosing recommendations, and not medical advice.

WPA Analysis

GHRP-2 Research Background and Calculator Data

GHRP-2 (Growth Hormone Releasing Peptide-2) is a synthetic hexapeptide GHS-R1a (ghrelin receptor) agonist developed by the Cyril Bowers laboratory at Tulane University through a series of papers in the late 1980s and 1990s that mapped the structure-activity relationships of opioid-derived growth hormone secretagogues. The lineage runs from Bowers' earlier GHRP-6 (the original member of the GHRP family) to GHRP-2 as the more potent and more selective second-generation variant, and from there to the non-peptide secretagogues that ultimately culminated in MK-677 (ibutamoren). GHRP-2 acts on the GHS-R1a receptor — the receptor that was later (in 1999, Kojima et al., Nature) identified as the native receptor for the endogenous peptide ghrelin — to potently amplify pulsatile GH release from pituitary somatotrophs. Its potency is meaningfully higher than GHRP-6 on a per-microgram basis, and its selectivity is cleaner: GHRP-2 shows less of the cortisol and prolactin co-stimulation that complicates GHRP-6 protocols, making it the preferred GHRP in the modern multi-peptide GH-axis research stack.

The published clinical literature on GHRP-2 includes several dose-finding and pharmacokinetic studies. The Frieboes et al. (1995) and Bowers et al. (1994) early characterization work established that IV GHRP-2 at 1mcg/kg produces reliable GH pulses in healthy adults; subsequent studies using subcutaneous delivery converged on the 100-300mcg per injection range as providing near-saturating pituitary GHS-R1a occupancy at a practical volume. The modern research community has largely standardized on GHRP-2 as one half of the GHRH + GHRP synergy stack: when a GHRH analog (CJC-1295 No DAC, Sermorelin, Tesamorelin) is co-injected with a GHRP (GHRP-2, GHRP-6, or Ipamorelin), the resulting GH pulse is synergistically larger than either agent alone — the mechanistic basis of every dual-peptide GH-axis protocol in the WPA compound library. GHRP-2 holds no FDA or EMA approval for any indication; it was studied at various points in corporate GH-secretagogue programs but never advanced to marketing, and remains a research-use compound.

Research background is separate from the calculator observations below. Calculator entries do not establish administration, safety, effectiveness, or the reasons for an input.

WPA DOSING INSIGHT

Dose and Frequency Calculator Inputs

The summaries use each chart's own period and, for frequency responses, its dose filter. Separate cohorts must not be combined into a protocol.

WPA RECONSTITUTION INSIGHT

Vial Size and BAC Water Calculator Inputs

Vial-size and BAC-water observations describe separate input distributions, not purchases or verified preparations. Separate modal inputs do not establish a joint protocol.

These figures come from anonymized WPA peptide calculator sessions.

All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.